These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 39056056)

  • 1. Clinical characteristics, anti-SARS-CoV-2 IgG titers, and inflammatory markers in individuals with post-COVID-19 condition in Kenya: a cross-sectional study.
    Theuri M; Ndombi EM; Thamaini P; Ogutu JO; Onsongo L; Madete JK; Ofula V; Gitau S; Mwangi G; Okemo P
    PeerJ; 2024; 12():e17723. PubMed ID: 39056056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population.
    Bichara CDA; da Silva Graça Amoras E; Vaz GL; da Silva Torres MK; Queiroz MAF; do Amaral IPC; Vallinoto IMVC; Bichara CNC; Vallinoto ACR
    BMC Infect Dis; 2021 May; 21(1):443. PubMed ID: 33992073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corona Virus Disease-19 serology, inflammatory markers, hospitalizations, case finding, and aging.
    Schaefer EJ; Dulipsingh L; Comite F; Jimison J; Grajower MM; Lebowitz NE; Lang M; Geller AS; Diffenderfer MR; He L; Breton G; Dansinger ML; Saida B; Yuan C
    PLoS One; 2021; 16(6):e0252818. PubMed ID: 34111164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and serological predictors of post COVID-19 condition-findings from a Canadian prospective cohort study.
    Collins E; Galipeau Y; Arnold C; Bhéreur A; Booth R; Buchan AC; Cooper C; Crawley AM; McCluskie PS; McGuinty M; Pelchat M; Rocheleau L; Saginur R; Gravel C; Hawken S; Langlois MA; Little J
    Front Public Health; 2024; 12():1276391. PubMed ID: 38784593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.
    Peghin M; Palese A; Venturini M; De Martino M; Gerussi V; Graziano E; Bontempo G; Marrella F; Tommasini A; Fabris M; Curcio F; Isola M; Tascini C
    Clin Microbiol Infect; 2021 Oct; 27(10):1507-1513. PubMed ID: 34111579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
    Kagucia EW; Ziraba AK; Nyagwange J; Kutima B; Kimani M; Akech D; Ng'oda M; Sigilai A; Mugo D; Karanja H; Gitonga J; Karani A; Toroitich M; Karia B; Otiende M; Njeri A; Aman R; Amoth P; Mwangangi M; Kasera K; Ng'ang'a W; Voller S; Ochola-Oyier LI; Bottomley C; Nyaguara A; Munywoki PK; Bigogo G; Maitha E; Uyoga S; Gallagher KE; Etyang AO; Barasa E; Mwangangi J; Bejon P; Adetifa IMO; Warimwe GM; Scott JAG; Agweyu A
    Influenza Other Respir Viruses; 2023 Sep; 17(9):e13173. PubMed ID: 37752065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.
    Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A
    Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan.
    Nagura-Ikeda M; Imai K; Kubota K; Noguchi S; Kitagawa Y; Matsuoka M; Tabata S; Miyoshi K; Ito T; Tamura K; Maeda T
    J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33861191
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
    Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
    J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study.
    Mink S; Drexel H; Leiherer A; Frick M; Reimann P; Saely CH; Fraunberger P
    Int J Infect Dis; 2024 Jun; 143():107016. PubMed ID: 38521446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.